B

Biogen

D
BIIB
USD
-0.32
(-0.1837%)
Market Closed
49,894.00
Volume
14.33
EPS
-
Div Yield
21.933
P/E
25,332,016,160.22
Market Cap
Today
-0.1837%
1 Week
0.012%
1 Month
-5.159%
6 Months
-20.611%
12 Months
-29.184%
Year To Date
-32.833%
All Time
-39.713%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
ABBV
ABBV
-0.78
(-0.3876%)
USD
AMGN
AMGN
0.28
(0.087%)
USD
GILD
GILD
6.23
(6.7946%)
USD
REGN
REGN
8.505
(1.0417%)
USD
SNY
SNY
-1.11
(-2.1003%)
USD
TAK
TAK
0.07
(0.5074%)
USD

Title:
Biogen

Sector:
Healthcare
Industry:
Drug Manufacturers - General
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Do you need help or have a question?
Contact Us